The patients, who were part of a small clinical trial led by researchers from New York’s Memorial Sloan Kettering (MSK) Cancer Center, saw their tumours vanish after being treated with an experimental drug called dostarlimab.
In the trial, researchers wanted to investigate if immunotherapy alone could beat rectal cancer that had not spread to other tissues, the organisation said.
Inspiration for the study came from a previous trial led by Dr Diaz, which saw patients taking a drug called pembrolizumab, the New York Times reported.
That trial, which involved patients with advanced cancer that resisted standard treatment, saw participants’ tumours stabilise, shrink and even vanish.
The results have provided “what may be an early glimpse of a revolutionary treatment shift”, Dr Hanna Sanoff, an oncologist at the Lineberger Comprehensive Cancer Center at the University of North Carolina, who was not involved in the trial, wrote in an editorial accompanying the paper.
“In order to provide more information regarding which patients might benefit from immunotherapy, subsequent trials should aim for heterogeneity in age, coexisting conditions, and tumour bulk”.
The original article contains 776 words, the summary contains 177 words. Saved 77%. I’m a bot and I’m open source!
This is the best summary I could come up with:
The patients, who were part of a small clinical trial led by researchers from New York’s Memorial Sloan Kettering (MSK) Cancer Center, saw their tumours vanish after being treated with an experimental drug called dostarlimab.
In the trial, researchers wanted to investigate if immunotherapy alone could beat rectal cancer that had not spread to other tissues, the organisation said.
Inspiration for the study came from a previous trial led by Dr Diaz, which saw patients taking a drug called pembrolizumab, the New York Times reported.
That trial, which involved patients with advanced cancer that resisted standard treatment, saw participants’ tumours stabilise, shrink and even vanish.
The results have provided “what may be an early glimpse of a revolutionary treatment shift”, Dr Hanna Sanoff, an oncologist at the Lineberger Comprehensive Cancer Center at the University of North Carolina, who was not involved in the trial, wrote in an editorial accompanying the paper.
“In order to provide more information regarding which patients might benefit from immunotherapy, subsequent trials should aim for heterogeneity in age, coexisting conditions, and tumour bulk”.
The original article contains 776 words, the summary contains 177 words. Saved 77%. I’m a bot and I’m open source!